Literature DB >> 8615322

Increased plasma adrenomedullin levels in chronic congestive heart failure.

K Kobayashi1, K Kitamura, T Etoh, Y Nagatomo, M Takenaga, T Ishikawa, T Imamura, Y Koiwaya, T Eto.   

Abstract

Adrenomedullin is a potent vasodilator peptide and occurs in circulating blood of human beings and experimental animals. Because it is produced in intact aorta of rats and in cultured vascular endothelial cells, adrenomedullin seems to participate in regulation of local vascular tone. To determine the pathophysiological roles of adrenomedullin, we investigated its plasma concentrations in 49 patients with heart failure. Plasma adrenomedullin levels increased significantly with advancing severity of the disease (New York Heart Association functional class I, 4.1 +/- 1.0; II, 5.6 +/- 1.6; III, 6.4 +/- 0.8; IV, 13.2 +/- 6.8 (fmol/l). Plasma adrenomedullin was correlated with pulmonary artery pressure (r = 0.44, p = 0.0114) and pulmonary capillary wedge pressure (r = 0.53, p = 0.0002). These findings indicate that adrenomedullin may play some important role in the pathophysiologic makeup of heart failure by its vasodilating effects against the concomitant exaggeration of humor pressor agents such as catecholamine and the renin-angiotensin system. Hemodynamic changes in pulmonary circulation may have some influence on the increased synthesis and secretion of plasma adrenomedullin in chronic congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8615322     DOI: 10.1016/s0002-8703(96)90185-4

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

Review 1.  [Role of adrenomedullin in the pathogenesis and treatment of cardiovascular dysfunctions and sepsis].

Authors:  M Westphal; J Sander; H Van Aken; C Ertmer; H D Stubbe; M Booke
Journal:  Anaesthesist       Date:  2006-02       Impact factor: 1.041

Review 2.  Novel neurohumoral factors in congestive heart failure: adrenomedullin.

Authors:  J G Lainchbury
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

3.  Cirrhotic cardiomyopathy.

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2008-11-11       Impact factor: 6.047

4.  Adrenomedullin increases fluid extravasation from the splenic circulation of the rat.

Authors:  S Kaufman; P Andrew; R Sultanian; Y Deng
Journal:  J Physiol       Date:  2001-07-15       Impact factor: 5.182

5.  Mid-regional-pro-adrenomedullin plasma levels are increased in obese adolescents.

Authors:  Silvia Del Ry; Manuela Cabiati; Vanessa Bianchi; Laura Caponi; Pietro Di Cecco; Benedetta Marchi; Emioli Randazzo; Chiara Caselli; Tommaso Prescimone; Aldo Clerico; Giovanni Federico
Journal:  Eur J Nutr       Date:  2015-05-29       Impact factor: 5.614

6.  Increased adrenomedullin immunoreactivity and mRNA expression in coronary plaques obtained from patients with unstable angina.

Authors:  T Ishikawa; K Hatakeyama; T Imamura; K Ito; S Hara; H Date; Y Shibata; Y Hikichi; Y Asada; T Eto
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

7.  Precursor proadrenomedullin influences cardiomyocyte survival and local inflammation related to myocardial infarction.

Authors:  Svenja Hinrichs; Katharina Scherschel; Saskia Krüger; Johannes Tobias Neumann; Michael Schwarzl; Isabell Yan; Svenja Warnke; Francisco M Ojeda; Tanja Zeller; Mahir Karakas; Till Keller; Christian Meyer; Stefan Blankenberg; Dirk Westermann; Diana Lindner
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-30       Impact factor: 11.205

8.  Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide.

Authors:  R De Matteo; C N May
Journal:  Br J Pharmacol       Date:  2003-11-17       Impact factor: 8.739

9.  The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus proBNP in systolic heart failure.

Authors:  Erkan Yıldırım; Mahir Cengiz; Nilgün Yıldırım; Kürşat Aslan; Emrah İpek; Ali Fuat Korkmaz; Fatih Rıfat Ulusoy; Engin Hatem
Journal:  Anatol J Cardiol       Date:  2014-12-25       Impact factor: 1.596

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.